Italia markets open in 3 hours 14 minutes

Incyte Corporation (INCY)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
79,72+0,47 (+0,59%)
Alla chiusura: 04:00PM EDT
80,19 +0,47 (+0,59%)
Dopo ore: 06:17PM EDT
Accedi per pubblicare un messaggio.
  • a
    baker bros top holdings YTD
    in case misery needs comapny
    $KOD -93%
    $BGNE -54%
    $ACAD -30%
    $SGEN -22%
    $INCY +3%
  • u
    $AGEN conversation
    BREAKING NEWS: $AGEN today has been granted Patent
    The present disclosure provides #multispecific (e.g., bispecific) #antibodies that specifically bind to human GITR and/or human #OX40
    $INCY partnered
  • K
    $SRPT conversation
    from Andrew Dunn:
    Top takeout targets, per new Credit Suisse investor survey:
    1. $CLVS
    2. $SRPT
    3. $ALDR
    4. $INCY
    5. $BMRN
    6. $GLPG
    7. $ALXN
    8. $IMMU
    9. $ICPT
    10. $VKTX
  • T
    $AGEN conversation
    BLAIR: #AACR21 $INCY $AGEN $MRTX $ITOS Abstract Highlights and Meeting Itinerary
    On Saturday, April 10, through Thursday, April 15, the American Association of Cancer
    Research (AACR) will host the first of two week-long virtual conferences, with the second to
    be hosted on Monday, May 17, through Friday, May 21. Full regular abstracts were posted to
    the AACR meeting website on March 10 with clinical trial and late-breaking abstracts to be
    released at the start of the conference, and in this note we highlight several important data
    presentations for our coverage list and other data of interest. In addition, an itinerary of all
    relevant presentations to our coverage list and the wider oncology landscape is appended at
    the end of this note.
    In particular, we highlight:
    • Incyte (INCY $83.18; Outperform) will be providing the first clinical update with the
    company’s A2A/A2B receptor inhibitor and hosting a conference call with investors
    (on Monday, April 12) to discuss the company’s broader adenosine targeting strategy,
    including a CD73 antibody. The adenosine pathway has garnered significant industry
    interest, and therapies targeting this pathway have led to monotherapy responses,
    although clear clinical development paths have yet to be established, in our opinion.
    • The next data point for TIGIT antibodies will come from iTeos (ITOS $34.54), which will
    present preliminary Phase I data with EOS884448 as a monotherapy. Recent management
    commentary suggests pharmacodynamic effects of EOS884448 will be focused on the
    periphery for the AACR presentation, with biopsy analysis coming later in the year. Recall
    other TIGIT antibodies have shown minimal activity as a monotherapy, with the most
    apparent benefit coming when combined with PD-(L)1 antibodies in PD-L1–positive
    patients. The company will also host an investor call on Monday, April 12.
    • Agenus (AGEN $2.89; Outperform) will provide an update from the ongoing trial
    evaluating the combination of AGEN1181, a next-generation CTLA-4 antibody with
    Fc enhancements, and balstilimab, the company’s PD-1 antibody. As of February, the
    company reported a 23% response rate (5/22 patients), achieving responses in tumors
    unlikely to respond to PD-(L)1 antibody monotherapy, including microsatellite stable
    colorectal and endometrial cancers. We will host a call with Agenus management on
    Saturday, April 10, to discuss the updated results (see page 5 for registration link).
    • Although mainly preclinical in nature, several companies will provide updates on KRAS
    G12C inhibitors, attempting to improve on the results presented to date by Amgen
    (AMGN $249.10; Market Perform) and Mirati (MRTX $173.91). In particular, the abstracts
    focus on proposed combination regimens, with preclinical efficacy reported for several
    combinations targeting the MAPK pathway.

    Agenus will present updated clinical data with the company’s novel Fc-enhanced CTLA-4 antibody, AGEN1181, for which the
    company has previously disclosed multiple confirmed responses as monotherapy and in combination with the PD1 antibody
    balstilimab. As of the most recent update, the combination of AGEN1181 and balstilimab resulted in a 23% response rate
    (5/22) across a variety of tumor types, including many that would not be expected to respond to PD-(L)1 monotherapy, such
    as microsatellite stable (MSS) colorectal cancer (CRC) and MSS endometrial cancer. These particularly tough-to-treat cancer
    types do not respond to PD-(L)1 monotherapy, making the initial data for AGEN1181 combination more impressive. Two MSS
    endometrial cancer patients have achieved responses, one on monotherapy AGEN1181 and a second on the combination with
    balstilimab. In addition, a confirmed partial response in an MSS CRC patient treated with the combination was also announced
    in February of this year. We continue to be encouraged by the safety profile of the drug and initial biomarker and efficacy data,
    and look forward to additional updates at the upcoming AACR meeting
  • p
    SunTrust just released a note stating that a series of strong data catalysts&disruptive medicines being commercialized or entering the clinic they recommend investors being overweight biotech. Their recommendations are:


    Our time is coming - just be patient.
  • a
    $INCY Incyte Corporation: The Phase I/II trial (NCT02697591) evaluating open- label, dose-escalation, safety study of INCAGN01876 in subjects with Advanced or Metastatic Solid Tumors has completed patient recruitment.
  • S
    $RIGL conversation
    Fellow Rigel shareholders: stay strong and stay patient. Despite the 350M upfront payment from Roche to Atea for a Phase 2 asset, a lot of promising biotechs were down today. $AGEN $BCRX (which has a potential oral treatment for Covid-19) $GTHX $INCY $BMRN $IMGN $CLVS $SGEN all down today. Have a nice weekend.
  • a

    A tougher FDA?🤔

    At least 8 clinical holds in past 2wks
    $GILD Magrolimab
    $TGTX U2 combo
    $CRTX COR388
    $MBIO MB-207
    $VKTX VK0214
    $YMTX YTX-7739
    $DYN DYNE-251
    $DNLI DNL919

    2 BLA/NDA withdrawn due to non-alignment on PMS
    $REGN cemiplimab in 2L cervical
    $INCY parsaclisib in lymphoma
  • P
    $INCY conversation
    jacosa: Any comment on the twit posting i just read?

    TheJ_stocktwits 3/1/22, 05:58 PM
    Hmmm seems too obvious INCY should buy out CTIC.
    From the cc today:
    Gil Joseph Blum Needham & Company, LLC, Research Division – Analyst
    ... From what I remember, patients who go on drug eventually go on ruxolitinib (INCY Jakafi), eventually all progressed to being thrombocytopenic. How long does that usually take?

    Jim Fong CTI BioPharma Corp. – SVP of US Commercial Operations
    Yes, Gil, typically, depending on the dose that they're on, when you look at the COMFORT trial, at their normal starting dose of 15 and 20 milligrams BID, you see about a 40% drop in platelet counts that occurs within the first 8 weeks. So it occurs pretty rapidly. Now as you go down in the doses, you start to see that taper off a bit. But again, you'll see that typically in the first 8 weeks of treatment.
  • T
    $INCY conversation
    news out on incyte that can't help the share price whats so over

    $INCY The FDA granted Incyte's Parsaclisib orphan status for its treatment of splenic marginal zone lymphoma.
  • P
    $AGEN conversation
    Garo Armen Retweeted

    Jennifer Buell

    2h2 hours ago
    More Jennifer Buell Retweeted Agenus Inc. ($AGEN)
    .@FierceBiotech your @9:45AM report by Nick Paul Taylor is wrong. Correct deal terms below: $AGEN retains 67% of royalties & 90% milestones. Call with questions.Jennifer Buell added,
    Agenus Inc. ($AGEN)

    Received $15 M from $XOMA for minority royalty interest in $INCY, $MRK partnerships. $AGEN retain 67% of royalties and 90% of milestone payments; Remain eligible for up to an additional $450 M and $85.5 M in milestones from @Incyte and @Merck, respectively

    1 reply 6 retweets 6 likes
    Reply 1 Retweet 6 Like 6

    Garo Armen

    3h3 hours ago
    There will also be unscrupulous characters who intentionally say wrong or do wrong regardless of the facts.

    0 replies 1 retweet 4 likes
    Reply Retweet 1 Like 4

    Garo Armen

    5h5 hours ago
    Today’s announcement is the first and the smallest of multiple transactions we expect to conclude this year. Agenus Closes $15 Million Partial Royalty Monetization With XOMA
  • A
    $EXEL conversation
    Goldman: Setting the stage for oncology M&A in 2018 Tax reform unlocks ~$160bn ex-US cash for potential M&A
    Potential top 5 acquirers: $CELG, $PFE, $GILD, $MRK, $JNJ ...expect the M&A focus to shift to ..: ( $AGIO (NDA filed), $CLVS, $EXEL, $INCY, $PBYI, $SGEN and $TSRO).
  • P
    Parsa Daman
    $AGEN conversation
    $INCY on tax reform, "will have best in class effective tax rate in 2-3 yrs after launch of a few more products"

    Great, then buy Agenus!
  • u
    $AGEN conversation
    doubles up on $AGEN shares , top buy in Q
    also $AGEN calls
    2nd $PACB
    3rd $OPK
    top $AGEN holders are $INCY and $GILD
  • M
    $CYCC conversation
    Cross post $INCY has near term FDA action that could ring up some handsome gains. I lost my money in CYCC and have since moved on.
  • T
    $INCY conversation
    even with news of a hope for baricitinib this stock goes down

    $INCY Lancet Journal author submits findings from use of artificial intelligence to make recommendations for suggestions of compounds likely to be effective as potential CoronaVirus treatment. #baricitinib feb3
  • P
    $CTIC conversation
    In a bigger picture, directly compare to JAKAFI
    in naive MF patients and show superiority in two major endpoints (SVR. TSS. ), better trends in Overall Survival. Potentially is the BEST jak inhibitor in every MF populations!
  • K
    $NKTR conversation
    Andy Biotech: Except you forget I/O legend $INCY Epacadostat

    $NKTR peg-IL2 vs $INCY IDO combo in 1L melanoma
    ORR: 53% (20/38) vs 65% (26/40)
    ORR in PD-L1+: 64% (14/22) vs 75% (9/12)
    ORR in PD-L1-: 39% (5/13) vs 56% (9/16)
    12mo PFS: 57% vs 63%
  • A
    Who’s next buyout coming AMRN and RDUS Buy who $GILD. $MRK. $INCY. $NVS
  • C
    $INCY conversation
    AnalystRatingsNetworkApr 6th, 2:10 pm
    Incyte given $85.00 PT by Raymond James Financial. buy rating. $INCY